Clinical Trial Update: Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting maraviroc 300 mg twice daily in HIV-negative male volunteers; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV Infections | Phase 1 | Status: COMPLETED